false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP10.01. First-Line Treatment for Driver-Gene Nega ...
EP10.01. First-Line Treatment for Driver-Gene Negative Metastatic Lung Adenocarcinoma with MPE: A Multicenter Retrospectively Study - PDF(Slides)
Back to course
Pdf Summary
This study aimed to analyze the effectiveness of different first-line treatment options for metastatic lung adenocarcinoma (MLA) without driver gene mutations. The study included 369 patients and compared the outcomes of standard platinum-based doublet chemotherapy (CT), CT plus immune checkpoint inhibitors (CTICI), and CT plus Bevacizumab (CTBev). The results showed that both CTICI and CTBev had significantly longer progression-free survival (PFS) and overall survival (OS) compared to CT alone. CTBev had superior outcomes compared to CTICI/CT in patients with PD-L1 < 1% and CTICI was more effective in patients with PD-L1 1-49%. In patients with PD-L1 > 50%, CTICI remained the optimal strategy. CTBev and CTICI also showed better control of malignant pleural effusion (MPE) compared to CT alone. However, CTICI had a better outcome in patients with PD-L1 > 50%. The study concluded that in MLA patients without driver gene mutations and presenting with MPE, the combination of CT and Bev or ICI is more effective and provides longer survival compared to chemotherapy alone. The expression of PD-L1 may also influence the choice between Bevacizumab or ICI. This study provides valuable insights into the treatment options for MLA patients without driver gene mutations and highlights the importance of personalized treatment strategies based on PD-L1 expression.
Asset Subtitle
Yuanyuan Zhao
Meta Tag
Speaker
Yuanyuan Zhao
Topic
Metastatic NSCLC: Cytotoxic Therapy
Keywords
metastatic lung adenocarcinoma
MLA
first-line treatment options
driver gene mutations
platinum-based doublet chemotherapy
immune checkpoint inhibitors
Bevacizumab
progression-free survival
overall survival
PD-L1 expression
×
Please select your language
1
English